On February 21, 2025, the FDA issued a Declaratory Order officially determining that the shortage of semaglutide injection products — the active ingredient in Novo Nordisk's Ozempic and Wegovy — is resolved, removing it from the agency's 506e shortage list where it had sat since 2022. The order triggers a wind-down of the large compounding-pharmacy market that sprang up around copycat GLP-1 injections, with enforcement-discretion deadlines of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities. The move reshapes the U.S. GLP-1 supply landscape after three years of scarcity-driven alternatives.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.